Hormonal therapy: Current and new directions

James N. Ingle

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The well-established hormonal risk factors for breast cancer and laboratory models of estrogen-driven breast cancer cell growth have long provided a rationale for hormonal therapy. After the early use of therapeutic oophorectomy, antiestrogens, now known as selective estrogen response modulators (SERMs), became widely used. Large-scale trials have now shown that the SERM prototype, tamoxifen, is effective for palliation in advanced breast cancer, for improvements in recurrence and mortality risk in early stage disease, local recurrence in ductal carcinoma in situ (DCIS), and as prevention for early stage breast cancer. Questions still remain about the optimal selection of patients for early stage disease, DCIS, and prevention. New highly potent aromatase inhibitors (Als) have now been tested in advanced stage disease, where they have become the treatment of choice for postmenopausal patients. Early results from a large randomized trial (Anastrozole, Tamoxifen, Alone or in Combination [ATAC]) suggest that the Al anastrozole is superior to tamoxifen in lowering the risk of recurrence. Fewer vaginal symptoms and hot flashes were seen with anastrozole, but more bone fractures in this group have raised the concern of long-term bone mineral density and other hormonal effects in a population of patients who are less likely to die of breast cancer than of other causes. Als are also being tested for primary prevention, and a hint of this benefit was seen in the ATAC trial. Signs of hormonal deficiency are a common problem in women who have been treated for breast cancer, and this adversely affects their overall quality of life. The controversies concerning hormonal supplementation and the limited data in this regard are discussed.

Original languageEnglish (US)
JournalBreast Journal
Volume9
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 2003

Fingerprint

Tamoxifen
Breast Neoplasms
Estrogens
Carcinoma, Intraductal, Noninfiltrating
Recurrence
Therapeutics
Hot Flashes
Aromatase Inhibitors
Estrogen Receptor Modulators
Bone Fractures
Ovariectomy
Therapeutic Uses
Primary Prevention
Bone Density
Patient Selection
Direction compound
Quality of Life
Mortality
anastrozole
Growth

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology

Cite this

Hormonal therapy : Current and new directions. / Ingle, James N.

In: Breast Journal, Vol. 9, No. SUPPL. 1, 01.2003.

Research output: Contribution to journalArticle

Ingle, James N. / Hormonal therapy : Current and new directions. In: Breast Journal. 2003 ; Vol. 9, No. SUPPL. 1.
@article{de244fdbb854452e9e30b93b99a8b611,
title = "Hormonal therapy: Current and new directions",
abstract = "The well-established hormonal risk factors for breast cancer and laboratory models of estrogen-driven breast cancer cell growth have long provided a rationale for hormonal therapy. After the early use of therapeutic oophorectomy, antiestrogens, now known as selective estrogen response modulators (SERMs), became widely used. Large-scale trials have now shown that the SERM prototype, tamoxifen, is effective for palliation in advanced breast cancer, for improvements in recurrence and mortality risk in early stage disease, local recurrence in ductal carcinoma in situ (DCIS), and as prevention for early stage breast cancer. Questions still remain about the optimal selection of patients for early stage disease, DCIS, and prevention. New highly potent aromatase inhibitors (Als) have now been tested in advanced stage disease, where they have become the treatment of choice for postmenopausal patients. Early results from a large randomized trial (Anastrozole, Tamoxifen, Alone or in Combination [ATAC]) suggest that the Al anastrozole is superior to tamoxifen in lowering the risk of recurrence. Fewer vaginal symptoms and hot flashes were seen with anastrozole, but more bone fractures in this group have raised the concern of long-term bone mineral density and other hormonal effects in a population of patients who are less likely to die of breast cancer than of other causes. Als are also being tested for primary prevention, and a hint of this benefit was seen in the ATAC trial. Signs of hormonal deficiency are a common problem in women who have been treated for breast cancer, and this adversely affects their overall quality of life. The controversies concerning hormonal supplementation and the limited data in this regard are discussed.",
author = "Ingle, {James N.}",
year = "2003",
month = "1",
doi = "10.1046/j.1524-4741.9.s1.4.x",
language = "English (US)",
volume = "9",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Hormonal therapy

T2 - Current and new directions

AU - Ingle, James N.

PY - 2003/1

Y1 - 2003/1

N2 - The well-established hormonal risk factors for breast cancer and laboratory models of estrogen-driven breast cancer cell growth have long provided a rationale for hormonal therapy. After the early use of therapeutic oophorectomy, antiestrogens, now known as selective estrogen response modulators (SERMs), became widely used. Large-scale trials have now shown that the SERM prototype, tamoxifen, is effective for palliation in advanced breast cancer, for improvements in recurrence and mortality risk in early stage disease, local recurrence in ductal carcinoma in situ (DCIS), and as prevention for early stage breast cancer. Questions still remain about the optimal selection of patients for early stage disease, DCIS, and prevention. New highly potent aromatase inhibitors (Als) have now been tested in advanced stage disease, where they have become the treatment of choice for postmenopausal patients. Early results from a large randomized trial (Anastrozole, Tamoxifen, Alone or in Combination [ATAC]) suggest that the Al anastrozole is superior to tamoxifen in lowering the risk of recurrence. Fewer vaginal symptoms and hot flashes were seen with anastrozole, but more bone fractures in this group have raised the concern of long-term bone mineral density and other hormonal effects in a population of patients who are less likely to die of breast cancer than of other causes. Als are also being tested for primary prevention, and a hint of this benefit was seen in the ATAC trial. Signs of hormonal deficiency are a common problem in women who have been treated for breast cancer, and this adversely affects their overall quality of life. The controversies concerning hormonal supplementation and the limited data in this regard are discussed.

AB - The well-established hormonal risk factors for breast cancer and laboratory models of estrogen-driven breast cancer cell growth have long provided a rationale for hormonal therapy. After the early use of therapeutic oophorectomy, antiestrogens, now known as selective estrogen response modulators (SERMs), became widely used. Large-scale trials have now shown that the SERM prototype, tamoxifen, is effective for palliation in advanced breast cancer, for improvements in recurrence and mortality risk in early stage disease, local recurrence in ductal carcinoma in situ (DCIS), and as prevention for early stage breast cancer. Questions still remain about the optimal selection of patients for early stage disease, DCIS, and prevention. New highly potent aromatase inhibitors (Als) have now been tested in advanced stage disease, where they have become the treatment of choice for postmenopausal patients. Early results from a large randomized trial (Anastrozole, Tamoxifen, Alone or in Combination [ATAC]) suggest that the Al anastrozole is superior to tamoxifen in lowering the risk of recurrence. Fewer vaginal symptoms and hot flashes were seen with anastrozole, but more bone fractures in this group have raised the concern of long-term bone mineral density and other hormonal effects in a population of patients who are less likely to die of breast cancer than of other causes. Als are also being tested for primary prevention, and a hint of this benefit was seen in the ATAC trial. Signs of hormonal deficiency are a common problem in women who have been treated for breast cancer, and this adversely affects their overall quality of life. The controversies concerning hormonal supplementation and the limited data in this regard are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0037263578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037263578&partnerID=8YFLogxK

U2 - 10.1046/j.1524-4741.9.s1.4.x

DO - 10.1046/j.1524-4741.9.s1.4.x

M3 - Article

AN - SCOPUS:0037263578

VL - 9

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - SUPPL. 1

ER -